Your session is about to expire
← Back to Search
Imaging Device
Real-time Eye Tracking and Imaging of the Eye in Diabetic Retinopathy Patients
N/A
Waitlist Available
Research Sponsored by PulseMedica
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new camera called the OSNAT800 IO that takes 3D pictures of the back of the eye and tracks eye movements in real-time. It aims to help doctors monitor patients with diabetic retinopathy, a common cause of vision loss. The goal is to see if this device can accurately track eye movements while taking detailed images.
Eligible Conditions
- Diabetic Retinopathy
- Retinal Imaging
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Successful performance of the real-time eye tracking function by post-image processing
Secondary study objectives
Device usability as assessed by a survey
Image Quality as assessed by user assessment of image quality parameters
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Retinal Imaging using the OSNAT800 IO deviceExperimental Treatment1 Intervention
Patients will have their eyes imaged with the OSNAT800 IO device in addition to a routine standard of care appointment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OSNAT 800 IO
2022
N/A
~60
Find a Location
Who is running the clinical trial?
PulseMedicaLead Sponsor
2 Previous Clinical Trials
275 Total Patients Enrolled